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ABSTRACT 
The α1-adrenergic receptors (α1-ARs) are involved in preconditioning. Given that certain 
intracellular pathways appear to be shared by preconditioning and postconditioning, it is 
possible that postconditioning could be also mediated by α1-ARs. The objective was to 
evaluate, by analyzing infarct size, if α1-ARs activation could trigger postconditioning; and 
also determine Akt and glycogen synthase kinase-3β (GSK-3β) phosphorylation. 
Langendorff-perfused rat hearts were subjected to 30 minutes of ischemia and 120 
minutes of reperfusion (I/R; n=8). After 30 min of global ischemia, we performed 6 cycles 
of reperfusion/ischemia of 10 sec each, followed by 120 min of reperfusion (postcon; n=9). 
In another postcon group, we administered prazosin during postcon protocol (postcon + 
prazosin; n=7). Finally, we repeated the I/R group but prazosin (prazosin; n=7), 
phenylephrine (PE; n=5) and clonidine (CL; n=6), were administered during the first 2 
minutes of reperfusion. Infarct size was measured using the triphenyltetrazolium chloride 
technique. Total and phosphorylated Akt and mitochondrial GSK-3β expression were 
measured by Western blot. Infarct size was 58.1±5.1% in I/R. Postcon and PE reduced 
infarct size to 40.1±2.9% and 35.3±5.5% respectively (p<0.05 vs. I/R). Postcon + prazosin 
administration abolished the beneficial effect on infarct size (61.6±4.5%; p<0.05 vs. 
postcon). Cytosolic Akt phosphorylation and mitochondrial GSK-3β phosphorylation were 
higher in the postcon and PE groups compared with the I/R and postcon + prazosin 
groups. Prazosin or clonidine administration did not modify neither protein expression nor 
infarct size. Our data demonstrate that postconditioning decrease infarct size by activation 
of the α1-AR pathway through Akt and GSK-3β phosphorylation. 
 
Keywords: Ischemic postconditioning, α-1 adrenergic receptor, infarct size, Akt, glycogen 
synthasa kinase 3β  
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INTRODUCTION 
 Brief intermittent periods of ischemia and reperfusion performed before long 
ischemia (termed ischemic preconditioning), have demonstrated protection of the 
myocardium against ischemia/reperfusion injury1. This cardioprotective strategy has limited 
clinical application in patients with acute myocardial infarction due to the inability to predict 
the moment of coronary artery occlusion. The concept of ischemic postconditioning may 
be useful, as it has been described as an entity by which brief periods of 
ischemia/reperfusion, performed at the onset of reperfusion, reduce infarct size2.  
 Different authors have provided evidence that the reduction on infarct size 
conferred by postconditioning could be triggered by activation of multiple types of cell 
membrane receptors which include adenosine A13, bradykinin B24 and opioids5. However, 
other types of membrane receptors that could be involved in the postconditioning 
mechanism are the α-adrenergic receptors (α1-ARs). The beneficial effects of preischemic 
α-ARs activation were shown by Gao et al.6, who found that activation of α1-ARs maintains 
cytosolic and mitochondrial Ca2+ homeostasis, improves contraction, and preserves ATP 
content under simulated ischemia/reperfusion. Studies by Banerjee et al.7 concluded that 
transient ischemic preconditioning is mediated by sympathetic neurotransmitter release 
and α-1-ARs stimulation. Conversely, Vasara et al.8 suggested that α1-ARs stimulation 
mimics ischemic preconditioning, but that it is not an essential component of the 
mechanism. However, there is no evidence of the possible role of α1-ARs as a trigger for 
postconditioning. Given that certain intracellular pathways, recruited at the time of 
myocardial reperfusion and appearing to be shared by both ischemic preconditioning and 
postconditioning, we hypothesized that activation of α1-ARs at the time of reperfusion is an 
important part of the mechanism of ischemic postconditioning. 
 Previous studies identified the survival kinases phosphatidylinositol 3-kinase 
(PI3K)-Akt as key players in the protection conferred by postconditioning9. However, 
studies evaluating the postconditioning mechanism did not consider the possibility of Akt 
phosphorylation via a α1-AR pathway in this protective mechanism. The inactivation of 
glycogen synthase kinase 3β (GSK-3β), as a consequence of its phosphorylation by Akt, 
has been implicated in the ischemic preconditioning mechanism10 and in 
postconditioning11. However, the effect of α1-ARs stimulation as part of the mechanism of 
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ischemic postconditioning on Akt and GSK-3β expression and in phosphorylation, is 
unknown. Thus, the aim of this study is to evaluate, by analyzing infarct size, if α1-ARs 
may trigger postconditioning. Since it’s known that Akt and GSK-3β phosphorylation 
participate in the protection mechanism of ischemic postconditioning, a second objective 
was to determine if the reduction of the infarct size by the induced activation of α1-ARs 
requires Akt and GSK-3β phosphorylation. 
 
MATERIAL AND METHODS 
 Wistar male rats (200 to 250 gr) were sacrificed with an intraperitoneal injection of 
pentobarbital (150 mg/kg)12. The heart was excised from the animals and placed in a 
perfusion system according to the Langendorff technique. All hearts were perfused with a 
Krebs-Henseleit buffer containing NaCl 118.5 mM, KCl 4.7 mM, NaHCO3 24.8 mM, 
KH2PO4 1.2 mM, Mg SO4 1.2 mM, CaCl2 1.8 mM and glucose 10 mM, pH 7.2 - 7.4, and 
gassed with 95% O2 – 5% CO2 at 37ºC. Two electrodes were sutured and connected to a 
pacemaker with a constant heart rate of 275 beats per minute (bpm). The experiments 
were approved by the Animal Care and Research Committee of the University of Buenos 
Aires (Protocol # 2948/2010). All the procedures were performed in compliance with the 
guidelines of the American Physiological Society “Guiding Principles for the Care and Use 
of Vertebrate Animals in Research and Training.” 
 A latex balloon connected to a pressure transducer (Deltram II, Utah Medical 
System) via a polyethylene cannula was inserted into the left ventricle (LV) for 
measurement of left ventricular pressure. The latex balloon was filled with water to achieve 
a left ventricular end diastolic pressure (LVEDP) of 8-10 mmHg. In addition, coronary 
perfusion pressure (CPP) was recorded using a pressure transducer connected to the 
perfusion line. All hearts were perfused at a constant flow. Coronary flow was adjusted to 
obtain a CPP of 70.5 ± 4.2 mmHg during the initial stabilization period. This flow level was 
maintained constant throughout the experiment.  
Experimental Protocols: 
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Ischemia/reperfusion group (I/R; n=8): Myocardial infarction was induced by 30 minutes of 
global no-flow ischemia followed by 120 minutes of reperfusion. Global no-flow ischemia 
was induced by abruptly decreasing the total coronary flow provided by the perfusion 
pump. 
Ischemic postconditioning group (postcon; n=9): The same protocol as in I/R group was 
repeated, but at the onset of reperfusion we performed  6 cycles of 10 sec of reperfusion 
followed by 10 sec of ischemia (2 minutes total intervention, ischemic postconditioning 
protocol). Reperfusion was then continued for 120 minutes. 
Ischemic postconditioning + prazosin group (postcon+prazosin; n=7): The same protocol 
as postcon was followed except for the administration of Prazosin Hydrochloride (Sigma) 
(α1-ARs blocker), diluted in isotonic saline solution at a 1 µM during ischemic 
postconditioning. It’s important to remark that prazosin was administered simultaneously 
while performing the postconditioning protocol. It was dissolved in the Krebs solution 
during the 6 cycles of short ischemia/ reperfusion (10 sec each). Once the 
postconditioning protocol was performed, hearts were perfused solely with Krebs- 
Henseleit solution until the protocol was complete. 
Prazosin group (n=7): The same protocol was followed as in I/R, except for the 
administration of Prazosin Hydrochloride (Sigma) at a 1 µM concentration during the entire 
first 2 minutes of the reperfusion period. This was performed in order to rule out the effects 
of the drug itself on myocardial viability. 
Phenylephrine group (PE; n=5): In order to assess if α1-ARs activation would trigger the 
postconditioning protection mechanism, we administered L-phenylephrine hydrochloride 
(Sigma), a selective α1-ARs agonist, diluted in isotonic saline solution at  50 µM, 5 µM and 
50 nM concentrations during 2 minutes at the beginning of reperfusion, (after 30 minutes 
of global ischemia). Reperfusion was then continued for 120 min. 
Clonidine group (CL; n=6): In this group we administered clonidine hydrochloride  
(Research Biochemicals International), a selective α2-ARs agonist, to confirm our 
hypothesis that α1-ARs receptors, and not α2-ARs, are the ones involved in myocardial 
protection.Clonidine was administered diluted in isotonic saline solution at a 10-6 M 
concentration during the first two minutes of reperfusion. Again, this administration was 
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performed after 30 minutes of global ischemia. Reperfusion was then continued for 120 
min.  
Normoxic group (Nx; n=4): This group was only used as a control group for the Western 
blot determinations. Hearts were stabilized during 20 min and then left ventricle samples 
were taken and deep frozen at –180ºC for their further processing. All the experimental 
groups were repeated and LV samples were taken at 20 min of reperfusion for the 
Western blot determination (n=4 per group). In the groups where the Western blot 
determinations were performed, the total perfusion time was of approximately 20 min, 
similar to the normoxic group used as the control for Western blot.  
Infarct Size Measurement 
     Infarct size was evaluated using 2, 3, 5-Triphenyltetrazolium chloride. After 120 
min of reperfusion, the hearts were deep frozen at -20° C during 30 minutes and then cut 
into 2 mm transverse slices from apex to base. The sections were incubated for 20 
minutes in a 1%  2,3,5- Triphenyltetrazolium chloride (Sigma) solution diluted in Tris buffer 
(AppliChem) (pH 7.4, 37°C) and then immersed in 10%  formalin. This technique stained 
viable sections red whereas non-viable sections remained unstained. All the sections were 
scanned and planimetered (Image Pro Plus, version 4.5). Infarct size was expressed as a 
percentage of the left ventricular area. 
Mitochondrial and Cytosolic Isolation and Fractioning: 
 Frozen samples were homogenized in 5 volumes of buffer MSHE (pH 7.6) with 
phosphatase and protease inhibitors (Halt (tm) Protease & Phosphatase Inhibitor Cocktail 
EDTA-free form Pierce), using a Potter Elvehjem homogenizer. Homogenates were 
centrifuged at 657 G for 10 minutes, filtered, and centrifuged again at 8,000 G for 10 
minutes. Pellets were resuspended in MSHE buffer (0.21 M mannitol/0.07 M sucrose/10 
mM Hepes, pH 7.4/1 mM EDTA/1 mM EGTA) with bovine serum albumin (BSA) and 30% 
Percoll. Suspensions were centrifuged at 8,000 G for 30 minutes at 4°C. Mitochondrial 
fractions were separated and rinsed once with MSHE buffer with BSA at 10,509 G for 10 
minutes at 4°C, twice with KCl 150 mM, and twice wi th MSHE buffer without BSA. 
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 The protein load was confirmed with an anti VDAC-1 antibody (1:700) (Santa Cruz 
Biotechnology INC.)13 and an anti β-actin antibody (1:1000) (Millipore) used as markers for 
outer mitochondrial membrane and cytosolic fraction, respectively. Removing the 
possibility that the mitochondrial fraction was contaminated, Western blot was performed 
where mitochondrial and cytosolic fractions were seeded and incubated with β-actin. As 
shown in Figure 1 Panel A, we used calreticulin antibody (1.1500) (Pierce) as an 
endoplasmic reticulum marker14. Calreticulin markings were observed in the cytosolic 
fraction, but were not observed in the mitochondrial fraction, discarding the possibility of 
contamination with endoplasmic reticulum. In Panel B, in the lanes where mitochondrial 
fractions were seeded, there is no evidence of the presence of β-actin, ruling out the 
possible contamination of the cytosolic fraction. To determine mitochondrial purity, two 
mitochondrial specific antibodies were used: TOM40 antibody15 (1:1000) (Santa Cruz) and 
VDAC13. TOM40 was included in Panel C (Figure 1), and it shows positive marking only in 
the mitochondrial fraction lanes. These findings, and the fact that VDAC was used as a 
loading control for the mitochondrial fractions, support the fact that the separation of the 
mitochondrial fraction was adequate.  
Western Blot 
 Protein samples from mitochondrial fractions (30 µg) were separated by SDS-
PAGE and transferred to a nitrocellulose membrane.  The samples were then incubated 
for one hour at room temperature in a blocking buffer containing 5% non fat milk and 5% 
BSA. Blots were then incubated overnight at 4ºC with rabbit polyclonal anti-GSK-3β 
(1:1,000) (Santa Cruz Biotechnology INC.), mouse monoclonal anti-Ser9 phospho GSK-3β 
(1:300) (Millipore), rabbit monoclonal anti-Akt (1:1,000) (Cell Signaling Technology) and 
rabbit monoclonal anti-Ser473 phospho Akt antibodies (1:1,000) (Cell Signaling 
Technology). The blots were then incubated with goat anti-rabbit (1:5,000) and goat anti-
mouse antibodies (1:3,000) (Millipore) at room temperature for 1 hour. Afterwards, they 
were rinsed with TBST. Blots were developed using the enhanced chemiluminescence 
method (BioRad) according to the manufacturer’s instructions. Relative levels of GSK-3β, 
phospho GSK-3β, Akt and phospho Akt, were quantified by densitometric analysis using 
Image Gauge 4.0 software (Fujifilm).  
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Statistical Analysis 
 Data are expressed as mean ± standard error of the mean (SEM). Inter-group 
comparisons were carried out using analysis of variance (one way-ANOVA) followed by t-
tests with the p value adjusted for multiple comparisons using the Bonferroni test. The data 
comparisons were not significant unless the corresponding p value was less than 0.05/k, 
where k represents the number of comparisons. 
 
RESULTS 
 Table 1 shows the behavior of the CPP and the infarct size following the 
administration of different concentrations of phenylephrine. Concentrations of 5 and 50 µM 
produced a significant increase in CPP at 30 min of reperfusion, and an increase in the 
infarct size in both groups compared to group I/R. This is the reason why we administered 
a lower concentration of phenylephrine (50 nM) where we could evidence a protective 
effect on the infarct size (p<0.05 vs. I/R) without significant changes in CPP at 30 minutes 
of reperfusion.  
 Table 2 shows the left ventricular developed pressure (LVDP), the LVEDP and the 
CPP values at baseline and during different reperfusion times. In all groups, LVDP, a 
contractility index, was significantly lower compared with the respective pre-ischemic 
values, but showed no significant differences among groups throughout the procedure. 
Regarding myocardial stiffness, represented by LVEDP, a significant increase at 30 min of 
reperfusion without differences among the groups was observed. Phenylephrine is a 
selective α1-ARs agonist and potent vasoconstrictor. We´d like to point out that the CPP 
values where phenylephrine was administered were similar to the other groups. 
 Figure 2 shows infarct size after 30 minutes of global no-flow ischemia and 120 min 
of reperfusion, expressed as a percentage of the total left ventricular area. In Panel A 
infarct size was 58.1±3.9% in the I/R group. Ischemic postconditioning significantly 
decreased infarct size to 40.1±2.9% (p<0.05 vs. I/R group).The administration of prazosin 
during the postconditioning protocol abolished the protective effect of postconditioning 
(63.5±3.4%, p<0.05 vs. postcon group). The infarct size in the group treated with prazosin 
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alone during the first 2 minutes of reperfusion was similar to that observed in the I/R group 
(58.8±3.6%), ruling out any possible effect of the drug per se. On the other hand, the 
activation of the α1-ARs with phenylephrine during reperfusion significantly reduced the 
infarct size compared with the I/R group (35.3 ± 5.5, p<0.05 vs. I/R). On the contrary, the 
activation of α2-ARs by the administration of clonidine during the first two minutes of 
reperfusion did not modify the infarct size compared with the I/R group (55.4±2.7%), 
demonstrating that α2-ARs do not mediate protection. Panel B shows representative slices 
of the different experimental groups. 
 Figure 3 shows cardiac Akt protein expression (Panel A and C) and 
phosphorylation (Panel B and D) in the cytosolic fraction. Cardiac Akt protein expression 
was displayed as a percentage of the normoxic group. There were no significant changes 
in cytosolic Akt protein expression; however, ischemic postconditioning induced a 
significant increase in Akt phosphorylation compared with the I/R and postcon + prazosin 
groups (Panel B). The activation of α1-ARs, when phenylephrine was administered during 
reperfusion, shows a significant increase in Akt phosphorylation compared to I/R group, 
demonstrating that α1-ARs would be involved in the protection. When we administered 
prazosin without ischemic postconditioning, we did not detect any changes compared with 
I/R group in the the cytosolic fraction (Panel D).  
 Figure 4 shows cardiac GSK-3β protein expression in the mitochondrial fraction. 
Cardiac GSK-3β mitochondrial protein expression was shown as a percentage of the 
normoxic group. There were no differences among groups in total cardiac GSK-3β protein 
expression (Panel A and C). In Panel B we show the normoxic, I/R, postconditioning, and 
postconditioning + prazosin groups. Ischemic postconditioning induced significant GSK-3β 
phosphorylation compared with the I/R group. Administration of prazosin during the 
ischemic postconditioning protocol decreased protein phosphorylation. In Panel D, we 
observed that prazosin without ischemic postconditioning did not modify GSK-3β 
phosphorylation compared with the I/R group. However α1-AR activation with 
phenylephrine administration increased GSK-3β phosphorylation compared with the I/R 
group, reaching similar values to the normoxic group. This finding suggests a link between 
mitochondrial GSK-3β and α1-AR activation. 
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DISCUSSION 
 The beneficial effect on infarct size was abolished by prazosin administration 
during the postconditioning protocol. The phenylephrine administration, an α1-ARs 
agonist, mimic the postconditioning effect and protected the heart against 
ischemia/reperfusion injury. Also, the activation of α1-ARs involves Akt and GSK-3β 
phosphorylation. Therefore the results of the present study demonstrate that α1-ARs 
triggers the protective effect of postconditioning in the model of isolated rat hearts used 
herein. 
 As we mentioned, ischemic postconditioning and phenylephrine increased Akt 
phosphorylation in the cytosol. Given that GSK-3β is a downstream substrate of Akt16 and 
is able to phosphorylate it, the present study sought to analyze the 
expression/phosphorylation state of this enzyme. The obtained results showed that GSK-
3β mitochondrial phosphorylation is increased in isolated rat hearts subjected to ischemic 
postconditioning and also in the presence of phenylephrine. In addition, it is noteworthy 
that administration of prazosin alone, without the postconditioning protocol, had no effect 
on infarct size, ruling out any possible effect of the drug per se.   
 Previous works used phenylephrine17,18 as a pharmacological tool with the aim of 
blocking α1-ARs in higher concentrations than the ones we used in the present research. 
An important difference is that in those studies, phenylephrine was administered before 
the ischemia period, and when trying to use the 50 µM, according to previous works17,18, 
we evidenced a powerful vasocontrictor effect. This, added to the fact that we 
administered it 30 minutes after ischemia, produced a significant increase on the infarct 
size and the CPP values (Table 1). Therefore, we performed experiments with different 
decreasing concentrations of phenylephrine , until we obtained a concentration that did not 
produce significant changes in the CPP behavior compared with the I/R protocol. We were 
able to evidence in this way a protective effect on the infarct size. 
 There is evidence supporting the hypothesis that α1-AR stimulation is an important 
mechanism in the protection conferred by ischemic preconditioning 6,7. A number of 
authors found that ischemic preconditioning and postconditioning share intracellular 
mechanisms, particularly during early reperfusion19, 9. In this regard, stimulation of any Gi 
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protein-coupled receptor has been shown to trigger preconditioning19, and a similar 
involvement of G protein-coupled receptors is being revealed for postconditioning. The 
present study contributes to the understanding of the mechanisms involved in 
postconditioning due to the fact that the blockade of α1-ARs during ischemic 
postconditioning modulates infarct size.  This suggests that these receptors may trigger 
the cardioprotection exerted by ischemic postconditioning. Consistent with our hypothesis, 
the lack of protection on the infarct size after the activation of α2-ARs with clonidine shows 
that protection would not be conferred by the activation of α2-ARs. Therefore, we are 
utilizing all this data and, as it was mentioned, even though we are not showing in a direct 
way the activation of α1-ARs, we strongly suggest that these receptors take part in the 
postconditioning protective mechanism, at least on isolated rat hearts.  
 The PI3K–Akt pathway is activated in response to the activation of a wide range of 
receptors, including G-protein-coupled receptors19. PI3K–Akt participates in different 
cellular processes by phosphorylating diverse substrates, including GSK-3β (glycogen and 
protein metabolism) 19. Tsang et al.16 demonstrated that ischemic postconditioning protects 
the isolated rat heart by activating the PI3K–Akt pathway at the time of myocardial 
reperfusion. Different studies have suggested that Akt may protect the myocardium 
against ischemia/reperfusion injury by acting at the level of the mitochondria. In this 
regard, Juhaszova et al.20 demonstrated that ischemic preconditioning protects myocytes 
by phosphorylating GSK-3β, a downstream target of Akt.  In the present study, we showed 
that ischemic postconditioning phosphorylates Akt in the cytosol and GSK-3β in the 
mitochondria. Regarding α1-ARs in myocardial ischemic protection, Zhao et al.21 
demonstrated the protective effect of preconditioning in rats over-expressing α1-ARs 
compared to non-transgenic rats as it can be evidenced by a reduction on infarct size. 
According to the authors, this protective effect involves an increase in extracellular signal-
regulated kinases (ERK), the mitogen-activated protein kinase (MEK) phosphorylation, and 
also the inducible nitric oxide syntase (iNOS) activity and expression. Their findings are in 
agreement with the present study´s results showing that blockade of α1–AR receptors 
abolishes the protective effect of ischemic postconditioning. The latter involves Akt and 
GSK-3β, which together with ERK, MEK and iNOS constitute the RISK-pathway, a group 
of proteins that activate during reperfusion and that are involved in the protection elicited 
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by ischemic postconditioning22,9. In concordance, our results showed that α1-ARs 
activation with phenylephrine increased Akt and GSK-3β phosphorylation. 
 It is known that GSK-3β contributes to different cellular processes including 
ischemia/reperfusion injury23. In contrast to many protein kinases, GSK-3β is active in 
resting cells and is inactivated by phosphorylation21. Inhibition of GSK-3β has been shown 
to reduce apoptosis and enhance cell survival, providing a plausible mechanism by which 
phosphorylation and inhibition of GSK-3β might mediate cardioprotection24. In this regard, 
Tong et al. showed that ischemic preconditioning reduces infarct size by increasing GSK-
3β phosphorylation through a PI3K–Akt dependent pathway10. Also Gomez et al. 
demonstrated that serine 9 phosphorylation of GSK-3β is required for cardioprotection by 
postconditioning, and it’s likely to act by inhibiting the opening of the mPTP at the time of 
reperfusion in a transgenic mouse model of reperfused myocardial infarction11. In 
concordance with the fact that GSK-3β has a cardioprotective effect, Terashima et al. 24 
demonstrated that the GSK-3β phosphorylation, at the time of reperfusion by a Protein 
Kinase C-ε (PKC-ε), PI3K-Akt and adenosine A2b receptor-dependent mechanism, 
contributes to the prevention of myocardial necrosis by pre-ischemic activation of the K+ 
mitochondrial channel. Also, it’s important to consider the role of matrix 
metalloproteinases, particularly type 2 (MMP-2), since it’s known that the increase of 
oxidative stress that occurs during reperfusion25 is one of the main triggers for the 
activation of this enzyme, and that both preconditioning26 and postconditioning27 decrease 
its activity. This is a fact that could partially explain the mechanisms of cardioprotection.  In 
relation to this concept, Kandasamy AD and Schulz R demonstrated that MMP-2 activates 
GSK3-beta by proteolytic removal of the N-terminal domain where the inhibitory 
phosphorylation of Serine 9 (Ser-9) occurs 28. Hence, this MMP-2-mediated increase of 
GSK-3β kinase activity may contribute to myocardial injury observed as a result of 
oxidative stress. Therefore we cannot discard that inhibition of MMP-2 by postconditioning 
could contribute by exerting its cardioprotective effect indirectly, given that the GSK-3β 
activity in a cell is dynamically regulated in response to stress. 
 The results of the present study demonstrate that activation of α1-ARs induced 
phosphorylation of Ser9-GSK-3β, since administration of prazosin during the ischemic 
postconditioning protocol decreased phospho-Ser9-GSK-3β expression and phenylephrine 
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increased phospho-Ser9-GSK-3β expression. Ballou et al.29 demonstrated that the α1-ARs 
can modulate GSK-3β activity in Rat-1 cells in two ways. One mechanism antagonizes 
insulin-induced Ser-9 phosphorylation to cause an increase in GSK-3β activity, and the 
second promotes phosphorylation of GSK-3β at Ser-9 to cause a decrease in GSK-3β 
activity. In agreement with our findings, Zhai et al.30 demonstrated a differential role of 
GSK-3β during myocardial ischemia/reperfusion. The authors showed that activation of 
GSK-3β is detrimental during reperfusion but protective during ischemia. Activation of 
GSK-3β during ischemia and inactivation of GSK-3β during reperfusion are both 
compensatory for the heart. Ischemic postconditioning acting in the reperfusion phase 
induces GSK-3β phosphorylation, decreasing its activity and conferring cardioprotection. 
 In the present study, ischemic postconditioning and phenylephrine administration 
reduced infarct size but were unable to improve ventricular function (contractile state and 
myocardial stiffness).The absence of improvement of left ventricular function in our study 
may be due to the presence of myocardial stunning areas peripheral to the infarct zone. In 
this sense, it has been well shown that the presence of a certain degree of postischemic 
dysfunction (stunned myocardium) reverts approximately after 48/72 hrs of reperfusion. 
Therefore the change on infarct size in acute experiments does not significantly influence 
the ventricular function 31. 
 In conclusion, the data obtained herein suggest that ischemic postconditioning 
decreases infarct size by activation of the α1-AR pathway, which could involve Akt and 
GSK-3β phosphorylation. These current results could indicate that after being 
phosphorylated, Akt may phosphorylate and inhibit GSK-3β. Further research must be 
conducted to better understand the mechanism of ischemic postconditioning 
cardioprotection, and to make it fully applicable in the clinical setting. 
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LEGENDS 
 
Figure 1: Panel A: Shows the calreticulin representative blot in mitochondrial and cytosolic 
fractions. This figure shows that the mitochondrial fraction was free from contamination 
with endoplasmic reticulum. Panel B: β-actin representative blot in mitochondrial fraction 
and cytosolic fraction. This figure is showed to discard mitochondrial contamination with 
cytosolic fraction. Panel C: TOM40 representative blot in mitochondrial and cytosolic 
fraction. This figure shows that TOM40, a mitochondrial membrane protein, is only present 
in the mitochondrial fraction, confirming its correct isolation. Nx: normoxic group; I/R: 
ischemia/reperfusion group; Postcon: Ischemic postconditioning group; PE: Phenylephrine 
group. 
 
Figure 2: Infarct size. Panel A shows infarct size expressed as a percentage of the total 
left ventricular area. Infarct size decreased significantly with ischemic postconditioning, 
and ischemic postconditioning + prazosin treatment abolished this beneficial effect. 
Administration of prazosin or clonidine alone, without postconditioning, did not modify 
infarct size, but phenylephrine administration reduced infarct size. Panel B shows 
representative slices of the different experimental groups. * p<0.05 vs I/R, Postcon, 
Postcon + prazosin and prazosin. I/R: Ischemia/reperfusion group; Postcon: Ischemic 
postconditioning group; PE: Phenylephrine group; CL: Clonidine 
 
Figure 3: Akt protein. Akt protein expression (Panels A and C) and phosphorylation 
(Panels B and D) in the cytosolic fraction are represented. There were no significant 
changes in cytosolic Akt protein expression (Panels A and C). However, ischemic 
postconditioning induced significant Akt phosphorylation which was blunted by postcon + 
prazosin (Panel B). Panel D showed that phenylephrine administration increased Akt 
phosphorylation, but prazosin alone did not modify Akt phosphorylation. Cardiac Akt 
protein expression and phosphorylation were expressed as a percentage of the normoxic 
group (Nx).  Equal protein loading was confirmed by β actin. * p<0.05 vs Nx and Postcon; 
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# p<0.05 vs. Nx and PE. I/R: Ischemia/reperfusion group; Postcon: Ischemic 
postconditioning group; PE: Phenylephrine group. 
 
Figure 4: Glycogen synthasa kinase 3β protein. Cardiac GSK-3β protein expression 
(Panels A and C) and phosphorylation (Panels B and D) in the mitochondrial fractions are 
represented. GSK-3β mitochondrial protein expression and phosphorylation were 
expressed as a percentage of the normoxic group (Nx). There were no differences among 
the groups in total cardiac GSK-3β protein expression (Panels A and C). Ischemic 
postconditioning induced significant GSK-3β phosphorylation compared with the I/R group, 
but administration of prazosin during the ischemic postconditioning protocol decreased 
protein phosphorylation (Panel B). Phenylephrine administration increased GSK-3β 
phosphorylation, but prazosin alone did not change GSK-3β phosphorylation compared 
with I/R (Panel D). Equal protein loading was confirmed by VDAC in the mitochondrial 
fraction. * p<0.05 vs. Nx and Postcon; # p<0.05 vs. Nx and PE. I/R: Ischemia/reperfusion 
group; Postcon: Ischemic postconditioning group; PE: Phenylephrine group; Nx: Normoxic 
group. 
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Table 1: Response of different concentrations of Phenylephrine administration on infarct size and 
coronary perfusion pressure (CPP) 
 
Groups Baseline CPP (mmHg) 30 min R CPP (mmHg)  Infarct size 
(%) 
I/R  66.1 ± 1.1 102.3 ± 3.1*  58.1±3.9 
PE 50 µM  67.9 ± 0.9 152.8 ± 13.5*&  82.5±5.3
&
 
PE 12.5 µM 67.8 ± 3.3 145.5 ± 9.6* &  74.4±6.2
&
 
PE 50 nM 63.1 ± 3.2 103.4 ± 7.3*  35.3±5.5
#
 
 
CPP: Coronary perfusion pressure; I/R: Ischemia/Reperfusion group; R: Reperfusion.  PE: Phenylephrine.                                       
*: p<0.05 vs respectively baseline value; &: p<0.05 vs. I/R group and PE 50nM group; #:p<0.05 vs. I/R group. 
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Table 2: Left ventricular function and coronary perfusion pressure. 
 Groups Baseline 2' Rep 15' Rep 30' Rep 
I/R 101.6 ± 3.6 15.8 ± 3.1* 11.3 ± 3.9* 12.6 ± 2.6* 
Postcon 105.4 ± 4.7  9.1 ± 1.4* 7.4 ± 1.4* 11.4 ± 1.8* 
Postcon + Prazosin 1 µM 103.9 ± 4.3 8.1 ± 1.2* 7.6 ± 0.8* 10.3 ± 2.3* 
Prazosin 1 µM 109.5 ± 3.2 15.4 ± 6.1* 6.7 ± 1.7* 9.9 ± 2.5* 
Phenylephrine 50 nM 102.1 ± 2.8 13.1 ± 1.7* 17.2 ± 4.9* 19.6 ± 3.8* 
LVDP 
(mmHg) 
Clonidine  10-6 M 99.7 ± 5.2 14.2 ± 8.5* 18.9 ± 5.2* 21.3 ±6.5* 
I/R 9.4 ± 0.3 110. ± 4.8* 110.9 ± 4.1* 104.7 ± 4.5* 
Postcon 7.8 ± 0.4 117.9 ± 4.2* 121.2 ± 4.2*  107.1 ± 4.5* 
Postcon + Prazosin 1 µM 7.3± 0.4 115.8 ± 9.9* 118.9 ± 7.7* 108.1 ± 9.8* 
Prazosin 1 µM 7.6± 0.8 92.8 ± 12.7* 126.4 ± 12.2* 111.3 ± 3.7* 
Phenylephrine 50nM 7.9 ± 0.8  94.1± 4.8* 104.1 ± 5.9* 100.3 ± 9.7* 
LVEDP 
(mmHg) 
Clonidine  10-6 M 8.1 ±0.7 99.8 ±5.9* 112.9±7.2* 107.8 ± 8.6* 
I/R 
 66.1 ± 1.1* 87.1 ± 2.3* 90.4 ± 2.7* 102.3 ± 3.1* 
Postcon 
 67.9 ± 0.9* 90.1 ± 2.5* 89.9 ± 2.7* 99.7 ± 3.5* 
Postcon + Prazosin 1 µM 67.8 ± 3.3 87.5 ± 2.7* 84.7 ± 3.6* 91.8 ± 9.3*  
Prazosin 1 µM 63.1 ± 3.2 85.8 ± 4.1* 101.1 ± 4.9* 106.1 ± 11.8*  
Phenylephrine 50nM 64.1 ± 2.7 83.3 ± 4.5* 89.3 ± 3.2* 103.4 ± 7.3* 
CPP 
(mmHg) 
Clonidine  10-6 M 71.1 ± 3.9. 89.5 ± 6.2* 93.2 ± 4.9* 101.8 ± 8.9* 
 
LVDP: Left ventricular developed pressure; LVEDP: Left ventricular end diastolic pressure; CPP: Coronary perfusion 
pressure. I/R: Ischemia/Reperfusion group; Postcon: ischemic postconditioning. *: p<0.05 vs baseline 
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